

WHAT IS CLAIMED IS:

1. Use of an anti-IL-23 antibody in the manufacture of a medicament for treating ulcerative colitis in a subject, wherein a therapeutically effective amount of the anti-IL-23 antibody that does not inhibit IL-12 is to be administered to the subject.
2. The use of claim 1 wherein the subject has moderately to severely active ulcerative colitis as determined by a colonoscopy.
3. The use of claim 1 wherein the anti-IL-23 antibody is to be administered by intravenous infusion.
4. The use of claim 3 wherein a total dosage of at least 700 mg, at least 1400 mg, at least 2100 mg, or at least 4200 mg of anti-IL-23 antibody is to be administered.
5. The use of claim 3 wherein the intravenous infusion comprises at least 70 mg of anti-IL-23 antibody in a volume of about 100 ml delivered over a period of at least 30 minutes.
6. The use of claim 1 wherein a plurality of intravenous infusions is to be administered.
7. The use of claim 6 wherein the plurality of intravenous infusions each comprises the same quantity of anti-IL-23 antibody.
8. The use of claim 1 wherein the anti-IL-23 antibody is to be administered subcutaneously.
9. The use of claim 8 wherein the anti-IL-23 antibody is to be administered in a plurality of doses.
10. The use of claim 9 wherein a total dosage of at least 105 mg or at least 210 mg of anti-IL-23 antibody is to be administered.
11. The use of claim 9 wherein each dose comprises about 70 mg anti-IL-23 antibody.
12. The use of claim 1 further comprising a plurality of doses of anti-IL-23 antibody, wherein a second dose is to be administered about two weeks after a first dose, and a third and subsequent doses are to be administered about four weeks after a preceding dose.
13. The use of claim 12 wherein the plurality of doses is about 10 doses.
14. The use of claim 12 wherein the first and second doses are to be administered by intravenous infusion and any subsequent dose is to be administered subcutaneously.

15. The use of claim 13 wherein each dose comprises at least 70 mg of anti-IL-23 antibody.
16. The use of claim 1 further comprising measuring the effect of the therapy using the modified Mayo Score/Disease Activity Index for Ulcerative Colitis.
17. The use of claim 16 wherein the therapy lowers the score of at least two components of the modified Mayo Score/Disease Activity Index for Ulcerative Colitis, wherein the components are selected from the group consisting of Stool Frequency, Rectal Bleeding, Endoscopy Findings and Physicians' Global Assessment.
18. The use of claim 1 wherein the anti-IL-23 antibody comprises the CDRH1 of SEQ ID NO:3, the CDRH2 of SEQ ID NO:4, the CDRH3 of SEQ ID NO:5, the CDRL1 of SEQ ID NO:6, the CDRL2 of SEQ ID NO:7 and the CDRL3 of SEQ ID NO:8.
19. The use of claim 1 wherein the anti-IL-23 antibody comprises the heavy chain variable region sequence of SEQ ID NO:1.
20. The use of claim 1 wherein the anti-IL-23 antibody comprises the light chain variable region sequence of SEQ ID NO:2.
21. The use of claim 1 wherein the anti-IL-23 antibody comprises the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:2.